Circulating Tumor DNA to Predict Radiographic and Pathologic Response to Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer
Oncologist. 2024 Jan 5:oyad336. doi: 10.1093/oncolo/oyad336. Online ahead of print.ABSTRACTDespite advances in treatment and response assessment in locally advanced rectal cancer (LARC), it is unclear which patients should undergo nonoperative management (NOM). We performed a single-center, retrospective study to evaluate post-total neoadjuvant therapy (TNT) circulating tumor DNA (ctDNA) in predicting treatment response. We found that post-TNT ctDNA had a sensitivity of 23% and specificity of 100% for predicting residual disease upon resection, with a positive predictive value (PPV) of 100% and a negative predictive value ...
Source: The Oncologist - January 5, 2024 Category: Cancer & Oncology Authors: Stephanie L Alden Valerie Lee Amol K Narang Jeffrey Meyer Susan L Gearhart Eric S Christenson Source Type: research

Circulating Tumor DNA to Predict Radiographic and Pathologic Response to Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer
Oncologist. 2024 Jan 5:oyad336. doi: 10.1093/oncolo/oyad336. Online ahead of print.ABSTRACTDespite advances in treatment and response assessment in locally advanced rectal cancer (LARC), it is unclear which patients should undergo nonoperative management (NOM). We performed a single-center, retrospective study to evaluate post-total neoadjuvant therapy (TNT) circulating tumor DNA (ctDNA) in predicting treatment response. We found that post-TNT ctDNA had a sensitivity of 23% and specificity of 100% for predicting residual disease upon resection, with a positive predictive value (PPV) of 100% and a negative predictive value ...
Source: The Oncologist - January 5, 2024 Category: Cancer & Oncology Authors: Stephanie L Alden Valerie Lee Amol K Narang Jeffrey Meyer Susan L Gearhart Eric S Christenson Source Type: research

Circulating Tumor DNA to Predict Radiographic and Pathologic Response to Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer
Oncologist. 2024 Jan 5:oyad336. doi: 10.1093/oncolo/oyad336. Online ahead of print.ABSTRACTDespite advances in treatment and response assessment in locally advanced rectal cancer (LARC), it is unclear which patients should undergo nonoperative management (NOM). We performed a single-center, retrospective study to evaluate post-total neoadjuvant therapy (TNT) circulating tumor DNA (ctDNA) in predicting treatment response. We found that post-TNT ctDNA had a sensitivity of 23% and specificity of 100% for predicting residual disease upon resection, with a positive predictive value (PPV) of 100% and a negative predictive value ...
Source: The Oncologist - January 5, 2024 Category: Cancer & Oncology Authors: Stephanie L Alden Valerie Lee Amol K Narang Jeffrey Meyer Susan L Gearhart Eric S Christenson Source Type: research

Circulating Tumor DNA to Predict Radiographic and Pathologic Response to Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer
Oncologist. 2024 Jan 5:oyad336. doi: 10.1093/oncolo/oyad336. Online ahead of print.ABSTRACTDespite advances in treatment and response assessment in locally advanced rectal cancer (LARC), it is unclear which patients should undergo nonoperative management (NOM). We performed a single-center, retrospective study to evaluate post-total neoadjuvant therapy (TNT) circulating tumor DNA (ctDNA) in predicting treatment response. We found that post-TNT ctDNA had a sensitivity of 23% and specificity of 100% for predicting residual disease upon resection, with a positive predictive value (PPV) of 100% and a negative predictive value ...
Source: The Oncologist - January 5, 2024 Category: Cancer & Oncology Authors: Stephanie L Alden Valerie Lee Amol K Narang Jeffrey Meyer Susan L Gearhart Eric S Christenson Source Type: research

CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial
CONCLUSIONS: The KENDO trial, although closed prematurely, adds further evidence supporting CDK4/6i + ET use in aggressive HR+/HER2-negative MBC instead of chemotherapy. PAM50 IS, genomic, and immunological features are promising biomarkers to personalize therapeutic choices.PMID:38175669 | DOI:10.1093/oncolo/oyad337 (Source: The Oncologist)
Source: The Oncologist - January 4, 2024 Category: Cancer & Oncology Authors: Francesco Schettini Michela Palleschi Francesca Mannozzi Fara Bras ó-Maristany Lorenzo Cecconetto Patricia Galv án Marita Mariotti Alessia Ferrari Emanuela Scarpi Anna Miserocchi Oriana Nanni Esther Sanfeliu Aleix Prat Andrea Rocca Ugo De Giorgi Source Type: research

CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial
CONCLUSIONS: The KENDO trial, although closed prematurely, adds further evidence supporting CDK4/6i + ET use in aggressive HR+/HER2-negative MBC instead of chemotherapy. PAM50 IS, genomic, and immunological features are promising biomarkers to personalize therapeutic choices.PMID:38175669 | DOI:10.1093/oncolo/oyad337 (Source: The Oncologist)
Source: The Oncologist - January 4, 2024 Category: Cancer & Oncology Authors: Francesco Schettini Michela Palleschi Francesca Mannozzi Fara Bras ó-Maristany Lorenzo Cecconetto Patricia Galv án Marita Mariotti Alessia Ferrari Emanuela Scarpi Anna Miserocchi Oriana Nanni Esther Sanfeliu Aleix Prat Andrea Rocca Ugo De Giorgi Source Type: research

First-in-Human Phase I Study of Minnelide in Patients With Advanced Gastrointestinal Cancers: Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity
CONCLUSIONS: This first-in-human, phase I clinical study identified a dose and schedule of Minnelide in patients with refractory GI cancers. The primary toxicity experienced was hematologic. Evidence of efficacy of Minnelide treatment in this group of patients was observed. The DCR ranged from ~2 to 6 months in 14/28 (50%) of evaluable patients. Studies in monotherapy and combination treatments are underway.PMID:38169017 | DOI:10.1093/oncolo/oyad278 (Source: The Oncologist)
Source: The Oncologist - January 3, 2024 Category: Cancer & Oncology Authors: Erkut Borazanci Ashok Saluja Jon Gockerman Mohana Velagapudi Ronald Korn Daniel Von Hoff Ed Greeno Source Type: research

A Novel Germline Mutation of BRCA1 and Integrated Analysis With Somatic Mutation in a Chinese Multi-Cancer Family
This study investigated the genomic mutations in a Chinese family with a history of ovarian, breast, and rectal adenocarcinoma. A novel germline mutation (Phe1695Val) in BRCA1 was identified through whole-exome sequencing. Subsequently, we performed whole-genome sequencing to identify somatic mutations and analyze mutational signatures in individuals carrying the novel germline mutation. Our findings revealed a correlation between somatic mutational signatures and the BRCA1 germline mutation in the proband with ovarian cancer, while no such association was observed in the tumor tissue from the patient with breast cancer. F...
Source: The Oncologist - December 30, 2023 Category: Cancer & Oncology Authors: Xiling Yang Li Shang Liren Yang Landi Sun Xiaoqian Tuo Sijia Ma Le Zhao Xu Li Wenfang Yang Source Type: research

Development of a Novel Comprehensive Hepatocellular Carcinoma Outcome Prognostic Scoring System With Integration of Imaging Features
CONCLUSIONS: Incorporation of standardized imaging characteristics to established clinical and lab predictors of outcome resulted in an improved predictive scoring system for patients with HCC.PMID:38159256 | DOI:10.1093/oncolo/oyad329 (Source: The Oncologist)
Source: The Oncologist - December 30, 2023 Category: Cancer & Oncology Authors: Hop S Tran Cao Russell G Witt Khaled M Elsayes Ali A Baiomy Lianchun Xiao Sarah Palmquist Sunyoung S Lee Yehia I Mohamed Armeen Mahvash Ching-Wei D Tzeng Yun Shin Chun Eugene Jon Koay Asif Rashid Manal M Hassan James C Yao Jean-Nicolas Vauthey Ahmed O Kas Source Type: research

A Novel Germline Mutation of BRCA1 and Integrated Analysis With Somatic Mutation in a Chinese Multi-Cancer Family
This study investigated the genomic mutations in a Chinese family with a history of ovarian, breast, and rectal adenocarcinoma. A novel germline mutation (Phe1695Val) in BRCA1 was identified through whole-exome sequencing. Subsequently, we performed whole-genome sequencing to identify somatic mutations and analyze mutational signatures in individuals carrying the novel germline mutation. Our findings revealed a correlation between somatic mutational signatures and the BRCA1 germline mutation in the proband with ovarian cancer, while no such association was observed in the tumor tissue from the patient with breast cancer. F...
Source: The Oncologist - December 30, 2023 Category: Cancer & Oncology Authors: Xiling Yang Li Shang Liren Yang Landi Sun Xiaoqian Tuo Sijia Ma Le Zhao Xu Li Wenfang Yang Source Type: research

Development of a Novel Comprehensive Hepatocellular Carcinoma Outcome Prognostic Scoring System With Integration of Imaging Features
CONCLUSIONS: Incorporation of standardized imaging characteristics to established clinical and lab predictors of outcome resulted in an improved predictive scoring system for patients with HCC.PMID:38159256 | DOI:10.1093/oncolo/oyad329 (Source: The Oncologist)
Source: The Oncologist - December 30, 2023 Category: Cancer & Oncology Authors: Hop S Tran Cao Russell G Witt Khaled M Elsayes Ali A Baiomy Lianchun Xiao Sarah Palmquist Sunyoung S Lee Yehia I Mohamed Armeen Mahvash Ching-Wei D Tzeng Yun Shin Chun Eugene Jon Koay Asif Rashid Manal M Hassan James C Yao Jean-Nicolas Vauthey Ahmed O Kas Source Type: research

Localized Myxofibrosarcoma: A Retrospective Analysis of Primary Therapy and Prognostic Factors in 134 Patients in a Single Institution
CONCLUSION: Adjuvant radiation had a positive impact on LRFS in all localized tumor stages, even in cT1 tumors. Chemotherapy did not have a significant impact on DMFS, regardless of tumor stage. Our findings indicate that myxofibrosarcoma may be a chemotherapy-resistant entity and a much closer monitoring is required, in case of neoadjuvant treatment.PMID:38141181 | DOI:10.1093/oncolo/oyad332 (Source: The Oncologist)
Source: The Oncologist - December 23, 2023 Category: Cancer & Oncology Authors: Athanasios Pogkas Peter Reichardt Per-Ulf Tunn Maya Niethard Mathias Werner Saeed Ghani Source Type: research

Localized Myxofibrosarcoma: A Retrospective Analysis of Primary Therapy and Prognostic Factors in 134 Patients in a Single Institution
CONCLUSION: Adjuvant radiation had a positive impact on LRFS in all localized tumor stages, even in cT1 tumors. Chemotherapy did not have a significant impact on DMFS, regardless of tumor stage. Our findings indicate that myxofibrosarcoma may be a chemotherapy-resistant entity and a much closer monitoring is required, in case of neoadjuvant treatment.PMID:38141181 | DOI:10.1093/oncolo/oyad332 (Source: The Oncologist)
Source: The Oncologist - December 23, 2023 Category: Cancer & Oncology Authors: Athanasios Pogkas Peter Reichardt Per-Ulf Tunn Maya Niethard Mathias Werner Saeed Ghani Source Type: research

Localized Myxofibrosarcoma: A Retrospective Analysis of Primary Therapy and Prognostic Factors in 134 Patients in a Single Institution
CONCLUSION: Adjuvant radiation had a positive impact on LRFS in all localized tumor stages, even in cT1 tumors. Chemotherapy did not have a significant impact on DMFS, regardless of tumor stage. Our findings indicate that myxofibrosarcoma may be a chemotherapy-resistant entity and a much closer monitoring is required, in case of neoadjuvant treatment.PMID:38141181 | DOI:10.1093/oncolo/oyad332 (Source: The Oncologist)
Source: The Oncologist - December 23, 2023 Category: Cancer & Oncology Authors: Athanasios Pogkas Peter Reichardt Per-Ulf Tunn Maya Niethard Mathias Werner Saeed Ghani Source Type: research

Localized Myxofibrosarcoma: A Retrospective Analysis of Primary Therapy and Prognostic Factors in 134 Patients in a Single Institution
CONCLUSION: Adjuvant radiation had a positive impact on LRFS in all localized tumor stages, even in cT1 tumors. Chemotherapy did not have a significant impact on DMFS, regardless of tumor stage. Our findings indicate that myxofibrosarcoma may be a chemotherapy-resistant entity and a much closer monitoring is required, in case of neoadjuvant treatment.PMID:38141181 | DOI:10.1093/oncolo/oyad332 (Source: The Oncologist)
Source: The Oncologist - December 23, 2023 Category: Cancer & Oncology Authors: Athanasios Pogkas Peter Reichardt Per-Ulf Tunn Maya Niethard Mathias Werner Saeed Ghani Source Type: research